ATE381938T1 - Verwendungen zur behandlung von fsh-verbundenen zuständen mit gnrh antagonisten - Google Patents

Verwendungen zur behandlung von fsh-verbundenen zuständen mit gnrh antagonisten

Info

Publication number
ATE381938T1
ATE381938T1 AT01913197T AT01913197T ATE381938T1 AT E381938 T1 ATE381938 T1 AT E381938T1 AT 01913197 T AT01913197 T AT 01913197T AT 01913197 T AT01913197 T AT 01913197T AT E381938 T1 ATE381938 T1 AT E381938T1
Authority
AT
Austria
Prior art keywords
related conditions
gnrh antagonists
fsh
treating
treating fsh
Prior art date
Application number
AT01913197T
Other languages
English (en)
Inventor
Marc Garnick
M Martha
Christopher Molineaux
Paoli Alex De
Original Assignee
Speciality Europ Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speciality Europ Pharma Ltd filed Critical Speciality Europ Pharma Ltd
Application granted granted Critical
Publication of ATE381938T1 publication Critical patent/ATE381938T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01913197T 2000-02-28 2001-02-28 Verwendungen zur behandlung von fsh-verbundenen zuständen mit gnrh antagonisten ATE381938T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18557400P 2000-02-28 2000-02-28
US18557300P 2000-02-28 2000-02-28
US23833800P 2000-10-05 2000-10-05
US23833700P 2000-10-05 2000-10-05

Publications (1)

Publication Number Publication Date
ATE381938T1 true ATE381938T1 (de) 2008-01-15

Family

ID=27497642

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01913197T ATE381938T1 (de) 2000-02-28 2001-02-28 Verwendungen zur behandlung von fsh-verbundenen zuständen mit gnrh antagonisten

Country Status (9)

Country Link
US (3) US7109171B2 (de)
EP (1) EP1261363B1 (de)
JP (1) JP2003525249A (de)
AR (1) AR033804A1 (de)
AT (1) ATE381938T1 (de)
AU (1) AU784866B2 (de)
CA (1) CA2401022A1 (de)
DE (1) DE60132072T2 (de)
WO (1) WO2001064236A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US7109171B2 (en) * 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
DK1512016T3 (da) * 2002-07-22 2006-07-03 Ardana Bioscience Ltd Screeningsmetode og antitumor-medikamentkandidat opnået derved
US20110086799A1 (en) * 2003-08-11 2011-04-14 Siler-Khodr Theresa M GnRH II Analogs and Uses Thereof in the Immune System
WO2005034987A1 (en) * 2003-10-13 2005-04-21 Studio Legale Avv Aldo Ferrini E Avv. Manuele Bianchi Use of lh for generating libido and reaching orgasm in female subjects
GB0616111D0 (en) 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
ES2643318T3 (es) 2006-10-24 2017-11-22 Repros Therapeutics Inc. Composiciones y métodos para suprimir la proliferación endometrial
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
US11278653B2 (en) 2009-01-29 2022-03-22 Baxter International Inc. Method and apparatus for trending automated peritoneal dialysis treatments
US8182673B2 (en) 2009-01-29 2012-05-22 Baxter International Inc. Drain and fill logic for automated peritoneal dialysis
US8142649B2 (en) 2009-01-29 2012-03-27 Baxter International Inc. Method for optimizing tidal therapies employing ultrafiltrate trending
US8936720B2 (en) 2010-09-17 2015-01-20 Baxter International Inc. Drain and fill logic for automated peritoneal dialysis
FR3055807B1 (fr) * 2016-09-15 2019-08-16 Edix Sa Dispositif connecteur-seringue pour administrer separement au moins deux produits en quantites controlees et en une seule injection
EP3600373A1 (de) * 2017-03-31 2020-02-05 Institut National de la Santé et de la Recherche Medicale Gnrh-antagonisten zur verwendung in der behandlung von frauen, die von polyzystischem ovarialsyndrom betroffen ist
EP4509173A3 (de) * 2017-06-05 2025-06-04 Kissei Pharmaceutical Co., Ltd. Dosierschemata für gonadotropinfreisetzende hormonantagonisten zur behandlung von gebärmutterfibroiden und zur reduzierung von menstruationsblutverlust
US11980621B2 (en) 2017-06-05 2024-05-14 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
MA54058A (fr) 2018-10-29 2021-09-08 ObsEva SA Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale
WO2021092187A1 (en) * 2019-11-07 2021-05-14 University Of North Texas Health Science Center At Fort Worth Detection and treatment of conditions related to luteinizing hormone/follicle-stimulating hormone (lh/fsh) levels

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935491A (en) 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US6162813A (en) 1996-05-20 2000-12-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US20070185033A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US6913761B1 (en) * 1998-07-20 2005-07-05 Peptech Limited Bioimplant formulation
US7005418B1 (en) * 1999-09-23 2006-02-28 Zentaris Gmbh Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
US7109171B2 (en) * 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
AU2002235348A1 (en) * 2001-01-17 2002-07-30 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators

Also Published As

Publication number Publication date
WO2001064236A2 (en) 2001-09-07
EP1261363B1 (de) 2007-12-26
JP2003525249A (ja) 2003-08-26
US20070015714A1 (en) 2007-01-18
AR033804A1 (es) 2004-01-07
AU784866B2 (en) 2006-07-13
DE60132072T2 (de) 2008-12-11
CA2401022A1 (en) 2001-09-07
WO2001064236A3 (en) 2002-05-10
EP1261363A2 (de) 2002-12-04
US7109171B2 (en) 2006-09-19
DE60132072D1 (de) 2008-02-07
US20090197813A1 (en) 2009-08-06
AU4188301A (en) 2001-09-12
US20020058035A1 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
DE60117977D1 (de) Vorrichtungen zur behandlung von harninkontinenz
DE60132072D1 (de) Verwendungen zur behandlung von fsh-verbundenen zuständen mit gnrh antagonisten
EP1324780A4 (de) Methoden zur behandlung von herzarrhythmie
DE60132089D1 (de) Vorrichtung zur behandlung von gasen miitels plasma
DE60124259D1 (de) Vorrichtung zur behandlung von migräne
DE60113496D1 (de) Verwendung von Glycyrrhizin zur Behandlung von Mastitis.
DE60028358D1 (de) Hmg1 antagonisten zur behandlung von entzündungen
DE60208780D1 (de) Vorrichtung zur abgabe von ablationsflüssigkeit zur behandlung von neoplasien
DE60038478D1 (de) Vorrichtung zur Injektion von Kontrastmitteln
DE60020171D1 (de) Gerät zur behandlung von bandscheiben
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE69922226D1 (de) Vorrichtung zur behandlung von ischämie
ATE323661T1 (de) Behandlung von mineralischen stoffen
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60234760D1 (de) Phenylindole zur behandlung von hiv
DE60014928D1 (de) Retinoide zur behandlung von emphysem
DE60112435D1 (de) Vorrichtung zur behandlung von abfällen
DE60228317D1 (de) N-aryl-n'-arylcycloalkyl-harnstoff als mch antagonisten zur behandlung von fettleibigkeit
DE10292400T1 (de) Kraftstoffbehandlungsbehälter
DE60224650D1 (de) Vorrichtung zur behandlung von vorhof-fibrillation
ATE493125T1 (de) Carbamatverbindungen zur behandlung von schmerz
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties